Complete Metabolic Response by 18F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Complete Metabolic Response by 18F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Published:2023-01-20 Issue:5 Volume:48 Page:417-419
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Uchida Yoichiro¹,Yoh Tomoaki¹,Fukui Ayaka²,Takai Atsushi³,Hatano Etsuro¹

Affiliation:

1. Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

2. Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan

3. Department of Gastroenterology and Hepatology, Kyoto, Japan.

Abstract

Abstract Nowadays, atezolizumab plus bevacizumab is recommended for advanced hepatocellular carcinoma (HCC) as the first-line systemic chemotherapy. Nevertheless, the data with regard to the tumor response still remain limited. We report a complete metabolic response assessed by 18F-FDG PET/CT in a 74-year-old man with advanced HCC who underwent atezolizumab plus bevacizumab followed by radical hepatectomy. Furthermore, pathological examination revealed that the tumor showed complete response for this therapy. This case suggests that 18F-FDG PET/CT represents clinical relevance as a useful approach for therapeutic assessment of immune-oncology drugs in HCC.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference8 articles.

1. Proposal of a new preoperative prognostic model for solitary hepatocellular carcinoma incorporating 18F-FDG-PET imaging with the ALBI grade;Ann Surg Oncol,2018

2. Quantitative assessment of microvascular invasion in hepatocellular carcinoma using preoperative serological and imaging markers;HPB (Oxford),2021

3. 18F-Fluorodeoxyglucose uptake in hepatocellular carcinoma as a useful predictor of an extremely rapid response to lenvatinib;Liver Cancer,2020

4. Total lesion glycolysis on 18F-FDG PET/CT is a better prognostic factor than tumor dose on 90Y PET/CT in patients with hepatocellular carcinoma treated with 90Y transarterial radioembolization;Clin Nucl Med,2022

5. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update;Liver Cancer,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Advanced Hepatocellular Carcinoma with Multiple Intrahepatic Metastases and Peritoneal Dissemination Treated using Atezolizumab plus Bevacizumab Combination Therapy, Resulted in Pathological Complete Response, with Concomitant Endoscopic Therapies for Early Gastric and Colorectal Cancers;Kanzo;2024-09-01

2. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08

3. Hepatic arterial infusion chemotherapy combined with bevacizumab plus a PD-1 inhibitor for gallbladder cancer with hepatic oligometastasis: a real-world study;Journal of Gastrointestinal Oncology;2024-02

4. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review;Clinical Journal of Gastroenterology;2023-12-10